Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation ExpenseEBIATLeasesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - OtherShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

AC Immune (ACIU) Receivables - Net (2018 - 2024)

AC Immune has reported Receivables - Net over the past 5 years, most recently at $28.4 million for Q3 2024.

  • Quarterly Receivables - Net changed N/A to $28.4 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $28.4 million through Sep 2024, changed N/A year-over-year, with the annual reading at $16.7 billion for FY2023, N/A changed from the prior year.
  • Receivables - Net was $28.4 million for Q3 2024 at AC Immune, down from $16.7 billion in the prior quarter.
  • Over five years, Receivables - Net peaked at $16.7 billion in Q4 2023 and troughed at $28.4 million in Q3 2024.